Baseline factors associated with haematological toxicity of pegylated interferon α-2a and ribavirin for the treatment of HCV infection in HIV coinfected patients

被引：0
|
作者：
Fuster, D
Galeras, JA
Gómez, G
Huertas, JA
González, J
Vilaró, J
Force, L
García, I
Roget, M
Cervantes, M
Pedrol, E
Tor, J
Ballesteros, AL
Planas, R
Videla, S
Sirera, G
Clotet, B
Tural, C
机构：
[1] Univ Barcelona, Hosp Germans Trias & Pujol, HIV Unit, Hepatol Unit, Barcelona, Spain
[2] Hosp del Mar, Hepatol Unit, Barcelona, Spain
[3] Univ Politecn Cataluna, Stat & Operat Res Dept, Barcelona, Spain
[4] Univ Madrid, Hosp La Paz, HIV Unit, Madrid, Spain
[5] Hosp Gen Vic, Internal Med Serv, Barcelona, Spain
[6] Hosp Mataro, Internal Med Serv, Barcelona, Spain
[7] Hosp Creu Roja De Barcelona, Internal Med Serv, Barcelona, Spain
[8] Hosp Terrassa, Internal Med Serv, Terrassa, Spain
[9] Hosp Parc Tauli, Internal Med Serv, Sabadell, Spain
[10] Hosp Granollers, Internal Med Serv, Barcelona, Spain
来源：
JOURNAL OF HEPATOLOGY | 2005年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
630
引用
收藏
页码：230 / 231
页数：2
相关论文
共 50 条
  • [1] Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-α2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy
    Fuster, D
    Huertas, JA
    Gómez, G
    Solà, R
    García, JG
    Vilaró, J
    Pedrol, E
    Force, L
    Tor, J
    Sirera, G
    Videla, S
    Planas, R
    Clotet, B
    Tural, C
    ANTIVIRAL THERAPY, 2005, 10 (07) : 841 - 847
  • [2] Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients
    Mira, Jose A.
    Lopez-Cortes, Luis F.
    Merino, Dolores
    Arizcorreta-Yarza, Ana
    Rivero, Antonio
    Collado, Antonio
    Rios-Villegas, Maria J.
    Gonzalez-Serrano, Mercedes
    Torres-Tortosa, Manuel
    Macias, Juan
    Valera-Bestard, Barbara
    Fernandez-Fuertes, Elisa
    Giron-Gonzalez, Jose A.
    Lozano, Fernando
    Pineda, Juan A.
    ANTIVIRAL THERAPY, 2007, 12 (08) : 1225 - 1235
  • [3] Hcv dynamics in HIV/HCV coinfected patients treated with pegylated interferon and ribavirin.
    Talal, AH
    Shata, MT
    Flynn, SM
    Dorante, G
    Laughlin, M
    Ribeiro, RM
    Perelson, AS
    HEPATOLOGY, 2002, 36 (04) : 205A - 205A
  • [4] Role of Pegylated Interferon-α-2a and Ribavirin Concentrations in Sustained Viral Response in HCV/HIV-Coinfected Patients
    Lopez-Cortes, L. F.
    Valera-Bestard, B.
    Gutierrez-Valencia, A.
    Ruiz-Valderas, R.
    Jimenez, L.
    Arizcorreta, A.
    Terron, A.
    Viciana, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (05) : 573 - 580
  • [5] Chorea during treatment with pegylated interferon and ribavirin in HIV-HCV coinfected patient
    Luisa Montes, Maria
    Maria Fraile, Jose
    Julian Gonzalez, Juan
    Ramon Arribas, Jose
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2009, 27 (01): : 60 - 61
  • [6] HCV treatment with pegylated interferon and ribavirin in patients with haemophilia and HIV/HCV co-infection
    Denholm, J. T.
    Wright, E. J.
    Street, A.
    Sasadeusz, J. J.
    HAEMOPHILIA, 2009, 15 (02) : 538 - 543
  • [7] Results of a study of prolonging treatment with pegylated interferon-α2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response
    Fuster, Daniel
    Planas, Ramon
    Gonzalez, Juan
    Force, Lluis
    Cervantes, Monel
    Vilaro, Josep
    Roget, Merce
    Garcia, Isobel
    Pedrol, Enric
    Tor, Jordi
    Ballesteros, Angel L.
    Salas, Anna
    Sirera, Guillem
    Videla, Sebastia
    Clotet, Bonaventura
    Tural, Cristina
    ANTIVIRAL THERAPY, 2006, 11 (04) : 473 - 482
  • [8] Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-α2a plus ribavirin treatment
    Massanella, Marta
    Tural, Cristina
    Papagno, Laura
    Garcia, Elisabet
    Jou, Antoni
    Bofill, Margarita
    Autran, Brigitte
    Clotet, Bonaventura
    Blanco, Julia
    ANTIVIRAL THERAPY, 2010, 15 (03) : 333 - 342
  • [9] Pegylated interferon alfa-2b and ribavirin in HIV/HCV-coinfected patients.
    Myers, RP
    Benhamou, Y
    Bochet, M
    Mehri, D
    Di Martino, V
    Valantin, MA
    Katlama, C
    Bricaire, F
    Poynard, T
    HEPATOLOGY, 2002, 36 (04) : 575A - 575A
  • [10] Safety and efficacy of a 24-week course of pegylated interferon α-2a and ribavirin for the treatment of acute HCV infection in HIV positive patients
    Dominguez, S. S. D.
    Ghosn, J. J. G.
    Schruninger, A.
    Valantin, M.
    Simon, A.
    Bollens, D.
    Campa, F.
    Bonnard, P.
    Slama, L.
    Autran, B.
    Thibault, V.
    Katlama, C.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S186 - S187
12345